Altimmune, Inc.
Close on Oct 19, 2026
- Market cap
- $413.54M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | $-0.21 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | – | $-0.33 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | Before market open | – | – | – |
Press releases
Announcements Altimmune filed with the SEC
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Altimmune Announces First Quarter 2026 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Altimmune Announces that Pemvidutide Achieved
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
48 - Week IMPACT Phase 2b Topline Data Presentation December 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Announces CEO Transition and Succession Plan
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K
Altimmune Announces Second Quarter 2025 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
IMPACT Phase 2b MASH Trial - Topline Results
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Altimmune Announces First Quarter 2025 Financial Results and Business Update
Material agreement · Results of operations · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
Material agreement · Results of operations · New financial obligation · Regulation FD disclosure · EX-99.2 to Form 8-K
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
This presentation has been prepared by Altimmune, Inc. ("we," "us," "our," "Altimmune" or the "Company") and includes certain
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
M. Scott Harris, MD, Chief Medical Officer
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Pemvidutide in Subjects with Non
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Week, Phase 1b Study of
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K